The new study, led by Ilke Sipahi of the Case Western Reserve University School of Medicine in Cleveland, tracked the incidence of cancer in five published studies involving a combined 61,000 patients where an ARB was compared to placebo. They found that 6% of the patients on placebo were diagnosed with cancer, compared to 7.2% of those who received one of the blood pressure drugs. The result was statistically significant. The study is being published online in Lancet Oncology. . . . James... Continuar leyendo

So sorry -- I can't resist this -- as so many often make the mistake of interchanging the German Merck KGaA (no relation) with the Whitehouse Station, New Jersey-based company -- that is covered by this blog. But when the capitalists' paper of record makes this rookies'-mistake, well. . . that is news: . . . .Merck & Co. of Whitehouse Station, N.J., has been working to correct problems that have affected aspects of its vaccine production since 2007. The Merck & Co. section of a graphic ... Continuar leyendo

With the very-recent FDA approval of Amgen's Prolia®, this dropout rate (or "switch-over" rate, if one prefers) is very likely to rise in the U.S. Note that 61 percent of patients go off of Fosamax® (or its generic equivalent, alendronate) within a year, according to a just released SDI analysis. This really is the hard winter's freeze setting in, on Fosamax: . . . .Currently, alendronate, sometimes filled as Fosamax but more frequently as the generic equivalent, is the most popular treatment... Continuar leyendo